SLAMF7/CS1 Antibody (YA8564)
(Synonyms: 19A; CD319; CRACC; CS1)SLAMF7/CS1 Antibody (YA8564) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to SLAMF7/CS1.
-
Host:
Mouse
-
Isotype:
IgG2b
-
Application:
IHC-P, FC
-
Reactivity :
Human
-
Formulation:
Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
|---|---|---|
| Dilution Ratio | 1:150-500 | 1:100 |
Product Details
SLAMF7/CS1 Antibody (YA8564) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to SLAMF7/CS1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 37.2 kDa
Full length human recombinant protein of human SLAMF7 produced in HEK293T cell.
Endogenous
Affinity purified
Non-conjugated
Unmodified
IgG2b
Product Properties
-
Appearance
Liquid
-
Formulation
Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Also acts inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:11802771). In LPS-activated monocytes negatively regulates production of pro-inflammatory cytokines (PubMed:23695528)|Isoform 3 does not mediate any NK cell activation
-
Subcellular Localization
Membrane
-
Expression
Tissue_Specificity: Expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. Expressed in monocytes. Isoform 3 is expressed at much lower level than isoform 1 -
Isoforms & Post-Translational Modification
Q9NQ25 has 7 isomers: Q9NQ25-1: 37421 Da (predicted); Q9NQ25-2: 25831 Da (predicted); Q9NQ25-3: 37026 Da (predicted); Q9NQ25-4: 17945 Da (predicted); Q9NQ25-5: 32581 Da (predicted); Q9NQ25-6: 22785 Da (predicted); Q9NQ25-7: 21316 Da (predicted).
-
Subunit
Isoform 1 binds to SH2D1A when its cytoplasmic tail is phosphorylated in the presence of FYN (in vitro); low affinity binding, the physiological relevance of the interaction is questioned
-
SwissProt ID
-
Synonyms
19A; CD319; CRACC; CS1
Documentation
Powered by Bioz
